"This is the first regulatory inspection and compliance approval conducted by MHRA-UK in line with the EU GMP regulations for plant 2," Claris Lifesciences said in a filing on BSE.
This approval is for products presented in glass ampoules manufactured in line 1 of plant 2, it added.
"This will help in enhancing capacities to grow in regulated markets, especially the European Union. The company's speciality injectables business saw a growth of 30 per cent in the last quarter," Claris Lifesciences said.
Ahmedabad based Claris Lifesciences is a sterile injectables pharmaceutical company with a market presence across 100 countries worldwide.
Shares of Claris Lifesciences were today trading at Rs 181.25 per scrip in the afternoon trade on BSE, up 3.36 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%